Merck to spin-off biosimilar drugs business to focus on Keytruda Medical Dialogues Bureau7 Feb 2020 9:15 AM IST Merck will retain its cancer drugs, including blockbuster cancer therapy Keytruda, vaccines, hospital and animal health businesses, the company...